TABLE 1.
Study characteristics.
| Study | Year | Enrolled patient | Design | Tx arm (no. of patients) | Tx line | ORR | DCR | PFS, mos | OS, mos |
|---|---|---|---|---|---|---|---|---|---|
| Reck | 2019 | Stage IV NS-NSCLC | Phase 3 Randomized | Atezo + PacCb (n = 402/) Atezo + Bev + PacCb (n = 400) Bev + PacCb (n = 400) |
1/2 | 40.6% 56.4% 40.2% |
NR | 6.7 (NR) 8.4 (8.0–9.9) 6.8 (6.0–7.0) |
19.5 (16.3–21.3) 19.8 (17.4–24.2) 14.9 (13.4–17.1) |
| Zhou | 2020 | Stage IIIb/IV NS-NSCLC | Phase 1b/2 Single group |
Cam + Apa (n = 105) | ≥2 | 30.9% | 73.3% | 5.7 (4.5–8.8) | 15.5 (10.9–24.5) |
| Herbst | 2019 | Stage IV NSCLC | Phase 1a/b Non-randomized |
Pembro + Ram (n = 27) | ≥2 | 30% | 85% | 9.7 (4.6–27.6) | 26.2 (11.8–nr) |
| Herbst | 2020 | Stage III/IV NSCLC | Phase 1 Non-randomized |
Pembro + Ram (n = 26) | 1 | 42.3% | 84.6% | 9.3 (4.0–nr) | nr |
| Chu | 2021 | Stage III/IV NSCLC | Phase 1 Non-randomized |
Sinti + Anlo (n = 22) | 1 | 77.3% | 100% | 15 (8.3–nr) | nr |
| Seto | 2020 | Stage III/IV NSCLC with high PD-L1 expression | Phase 2 Single group |
Atezo + Bev (n = 39) | 1 | 64.1% | NR | 15.9 (5.65–15.93) | nr |
| Lee | 2020 | Stage IIIb/IV NS-NSCLC | Phase 3 Randomized |
Niv + Bev + PacCb (n = 275) Placebo + Bev + PacCb (n = 275) |
1 | 61.5% 50.5% | NR | 12.1 (9.8–14) 8.1 (7.0–8.5) |
25.4 (21.8–nr) 24.7 (20.2–nr) |
| Taylor | 2020 | Stage III/IV NSCLC | Phase 1b/2 Single group |
Pembro + Lenva (n = 21) | ≥1 | 33.3% | 80.9% | 5.9 (2.3–13.8) | NR |
| Nishio | 2020 | Stage IV NS-NSCLC | Phase 3 part 1 Randomized Double-blind | Pembro + Lenva + PemCb/Cis (n = 13) | 1 | 69.2% | 92.3% | NR | NR |
| Bang | 2020 | Stage IIIb/IV NSCLC | Phase 1a/b Non-randomized |
Durva + Ram (n = 28) | ≥2 | 11% | 57% | 2.7 (1.6–5.8) | 11 (6.2–15.2) |
| Ardeshir-Larijani | 2021 | Stage IIII NS-NSCLC | Phase 2 Single group |
Atezo + Bev + PemCb (n = 30) | 1 | 35.71% | 92.85% | NR | NR |
| Yang | 2021 | Stage IV NSCLC | Phase 3 Randomized |
Pembro + Lenva (n = 309) Pembro + Placebo (n = 314) |
1 | 40.5% 27.7% |
NR | 6.6 (6.1–8.2) 4.2 (4.1–6.2) |
14.1 (11.4–19.0) 16.4 (12.6–20.6) |
| Ren | 2022 | Stage IIIb-IV NS-NSCLC | Phase 1b/2 Single group (cohort 4) |
Cam + Apa (n = 25) | 1 | 40% | 92% | 9.6 (5.5–nr) | nr |
| Han | 2021 | Stage IIIb-IV NS-NSCLC | Phase 3 Randomized |
Penpulimab + Anlo (n = 26) | 1 | 57.1% | 90.5% | nr | nr |
| Zhou | 2019 | Stage IIIb/IV NS-NSCLC | Phase 1/2 Single group (cohort 1) |
Cam + Apa (n = 96) | ≥2 | 30.8% | 82.4% | 5.9 (5.5–10.3) | nr |
| Neal | 2021 | Stage IV NSCLC | Phase 1b Single group |
Atezo + cabozantinib (n = 30) | ≥2 | 23% | 83% | NR | nr |
| Leal | 2021 | Stage III-IV NS-NSCLC | Phase 2 Single group |
Nivo + sitravatinib (n = 68) | ≥2 | 16% | NR | 6 | 15 (9.3–21.1) |
| Han | 2021 | Stage IIIb-IV NSCLC | Phase 3 Randomized |
TQ-B2450 (PD-L1)+Anlo (n = 68) TQ-B2450 (PD-L1) (n = 33) |
≥2 | 30.9% 3% |
73.5% 54.6% | 6.9 (5.3–12.4) 2.7 (1.4–4.7) |
nr nr |
| Lee | 2022 | Stage IIIb/IV NSCLC | Phase 2 Single group (stages II) |
Atezo + Bev (n = 24) | ≥3 | 12.5% | 87.5% | 5.6 (4.1–7.1) | 14 (10.7–17.4) |
| Gao | 2021 | EGFR-mutated NSCLC | Phase 1b/2 Single group (cohort 2) |
Cam + Apa (n = 40) | ≥3 | 20% | 62.5% | 3.2 (1.5–6.4) | nr |
| Gao | 2022 | Stage IIIb/IV non-central squamous NSCLC | Phase 1b/2 Single group (cohort 3) |
Cam + Apa (n = 25) | ≥2 | 32% | 84% | 6.0 (3.6–8.3) | 12.8 (6.4–nr) |
| Gadgeel | 2018 | Stage IIIb/IV NS-NSCLC | Phase 1/2 Single group (cohort B) |
Pembro + Bev + PacCb (n = 25) | 1 | 56% | 76% | 7.1 (4.2–14.3) | 16.7 (8.5–nr) |
| Lu | 2021 | Stage IIIb-IV EGFR-mutated advanced NS-NSCLC | Phase 3 Randomized |
Sinti + Bev + PemCs (n = 148) Sinti + PemCs (n = 145) PemCs (n = 151) |
≥2 | 43.9% 33.1% 25.2% |
NR NR NR |
6.9 (6.0–9.3) 5.6 (4.7–6.9) 4.3 (4.1–5.4) |
nr nr nr |
Tx, treatment; NS, non-squamous; NSCLC, non-small cell lung cancer; Atezo, atezolizumab; Bev, bevacizumab; PacCb, paclitaxel plus carboplatin; Cam, camrelizumab; Apa, apatinib; Pembro, pembrolizumab; Ram, ramucirumab; Sin, sintilimab; Anlo, anlotinib; Niv, nivolumab; Len, lenvatinib; PemCb, pemetrexed plus carboplatin; Durva, durvalumab; Cis, cisplatin; mos, months; ORR, objective response rate; DCR, disease control rate; PFS, progression-free survival; OS, overall survival; NR, not reported; nr, not reached.